Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion

Main Article Content

Linda Stein Gold
Mark Lebwohl
Neal Bhatia
Douglas DiRuggiero
Abby Jacobson
Radhakrishnan Pillai

Keywords

Psoriasis, Plaque Psoriasis, Topical, Corticosteroid, Halobetasol, Retinoid, Tazarotene, Cessation, Treatment Success

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.

2. Benhadou F, et al. Dermatology. 2019;235(2):91-100.

3. Tanghetti E, et al. J Dermatolog Treat. 2019:1‑8.

4. Chandraratna RA. J Am Acad Dermatol. 1997;37(2 Pt 3):S12-17.

5. Duvic M, et al. J Am Acad Dermatol. 1997;37(2 Pt 3):S18-24.

6. Tanghetti E, et al. J Drugs Dermatol. 2018;17(12):1280-1287.